Taxane-refractory PCa: Regimens offer modest results

Atlanta-A trial of drug regimens in hormone-refractory prostate cancer came up with only modest results, but it did take an important first step: It is one of the first prospective trials conducted in taxane-refractory disease.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.